Sanofi-Synthélabo has referred
to the French stock market regulatory authorities (COB)
following a financial analyst’s report concerning
one of the company’s compounds in development
Sanofi-Synthélabo has referred
to the French stock market regulatory authorities, the Commission des Opérations de
Bourse (COB – equivalent to the U.S. Securities and Exchange Commission), following
the publication of a financial analyst report issued yesterday by Dresdner Kleinwort
Wasserstein, which subsequently appeared in the press.
In this report, which claims as its
source an article from a scientific journal (FASEB), published this summer, it is
stated that a product in clinical development, SR141716A (rimonabant), could have a
potentially carcinogenic activity.
However, this article from the
scientific journal in no way evokes a carcinogenic activity for this product. On the
contrary, it even indicates that, in high concentrations in vitro, the product could
potentially inhibit cellular proliferation.
Given the totally misleading character of these comments, Sanofi-Synthélabo reserves all its legal rights.
_________________
This release contains statements
that constitute forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are based on management’s
current expectations or beliefs and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those described in the
forward-looking statements. The following factors, among others, could cause actual
results to differ materially from those described in the forward-looking statements : the
ability of Sanofi-Synthélabo to expand its presence profitably in the United
States; the success of Sanofi-Synthélabo’s research and development programs;
the ability of Sanofi-Synthélabo to protect its intellectual property rights; and
the risks associated with reimbursement of health care costs and pricing reforms,
particularly in the United States and France. Sanofi-Synthélabo does not undertake
any obligation to provide updates or to revise any forward-looking statements.
_________________
|
